Marrone Bio Innovations to Present at LD Micro 500 Virtual Investor Conference
Marrone Bio Innovations (NASDAQ: MBII) announced its participation in the LD 500 virtual investor conference from September 1-4, 2020. CFO Jim Boyd will present on September 2 at 1:20 PM ET, followed by one-on-one meetings with CEO Kevin Helash. The conference aims to connect growth-oriented companies with investors. Marrone Bio focuses on sustainable bioprotection and plant health solutions, having screened over 18,000 microorganisms and 350 plant extracts, resulting in a robust product portfolio backed by over 400 patents.
- None.
- None.
DAVIS, Calif., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (“Marrone Bio” or the “Company”), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, today announced that management will present at the LD 500 virtual investor conference, hosted by LD Micro and taking place virtually September 1 – 4, 2020.
Jim Boyd, Chief Financial Officer of Marrone Bio, is scheduled to host a virtual presentation during the conference as follows and will participate in one-on-one meetings with Chief Executive Officer Kevin Helash throughout the day.
LD 500 Virtual Investor Conference
Date: Wednesday, September 2, 2020
Time: 1:20 p.m. Eastern time (10:20 a.m. Pacific time) – Track 1
Webcast: https://www.webcaster4.com/Webcast/Page/2019/36186
A live audio webcast and archive of the conference presentation will be available using the webcast link above. For more information on the LD 500 virtual investor conference or to schedule a one-on-one, please contact your LD Micro representative.
About Marrone Bio Innovations
Marrone Bio Innovations Inc. (NASDAQ: MBII) is a growth-oriented company leading the movement to a more sustainable world through the discovery, development and sale of innovative biological products for crop protection, plant health and waterway systems treatment that help customers operate more sustainably while increasing their return on investment. MBI has screened over 18,000 microorganisms and 350 plant extracts, leveraging its in-depth knowledge of plant and soil microbiomes enhanced by advanced molecular technologies and natural product chemistry to rapidly develop seven product lines. Supported by a robust portfolio of over 400 issued and pending patents, MBI’s currently available commercial products are Regalia®, Stargus®, Grandevo®, Venerate®, Majestene®, Haven®, Pacesetter™, Zelto® Jet Oxide® and Jet Ag® and Zequanox®, with a next-generation insecticide-nematicide, a breakthrough bioherbicide and a biofumigant in the Company’s product pipeline. MBI’s Pro Farm Finland-based subsidiary employs a proprietary technology derived from wood waste to stimulate plant growth and improve plant health, resulting in improved yields and crop quality. Products include UBP™ 110, Foramin®, UBP™ Seed Treatment, Foramin® ST.
Learn more about Marrone Bio Innovations at www.marronebio.com. We also use our investor relations website, https://investors.marronebio.com, as well as our corporate Twitter account, @Marronebio, as means of disclosing material non-public information, and encourage our investors and others to monitor and review the information we make public in these locations. Follow us on social media: Twitter, LinkedIn and Instagram.
Marrone Bio Innovations Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date. Examples of such statements include statements regarding the timing of Helash’s employment and appointment to the company’s board of directors and the company’s goals for future performance. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company’s control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including the recent uncertainty in the global economy and industry-specific economy caused by the COVID-19 pandemic, consumer, regulatory and other factors affecting demand for the Company’s products, weather, regulatory and other factors affecting demand for the MBI’s products, any difficulty in marketing MBI’s products in its target markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers, and adverse decisions by regulatory agencies and other relevant third parties. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of current information, future events or otherwise.
Investor Relations Contact:
Greg Falesnik or Luke Zimmerman
MZ Group – MZ North America
Phone: 949-385-6449
MBII@mzgroup.us
FAQ
What is the LD 500 virtual investor conference schedule for MBII?
Who will represent Marrone Bio at the LD 500 conference?
What are the main products of Marrone Bio Innovations?
How does Marrone Bio Innovations support sustainable agriculture?
Where can I access the webcast for Marrone Bio's presentation?
